Insider Selling: LeMaitre Vascular (NASDAQ:LMAT) Director Sells $560,388.40 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Bridget Ross sold 5,044 shares of LeMaitre Vascular stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $111.10, for a total transaction of $560,388.40. Following the transaction, the director directly owned 3,942 shares of the company’s stock, valued at approximately $437,956.20. This represents a 56.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

LeMaitre Vascular Stock Up 1.0%

Shares of NASDAQ:LMAT opened at $98.17 on Thursday. The firm has a market capitalization of $2.24 billion, a PE ratio of 36.23, a price-to-earnings-growth ratio of 2.70 and a beta of 0.60. The business has a 50 day simple moving average of $109.69 and a two-hundred day simple moving average of $94.82. LeMaitre Vascular, Inc. has a 1 year low of $78.35 and a 1 year high of $118.01. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm had revenue of $66.55 million for the quarter, compared to the consensus estimate of $66.67 million. During the same period in the prior year, the business posted $0.48 earnings per share. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, equities analysts predict that LeMaitre Vascular, Inc. will post 3 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st will be given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 36.90%.

Institutional Trading of LeMaitre Vascular

Hedge funds have recently bought and sold shares of the stock. M&T Bank Corp boosted its position in LeMaitre Vascular by 2,240.5% during the 4th quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock valued at $32,283,000 after acquiring an additional 381,061 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of LeMaitre Vascular by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock worth $31,731,000 after acquiring an additional 231,157 shares in the last quarter. First Trust Advisors LP raised its position in shares of LeMaitre Vascular by 35.4% in the 3rd quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier’s stock worth $72,541,000 after acquiring an additional 216,919 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of LeMaitre Vascular by 292.3% during the 1st quarter. Bessemer Group Inc. now owns 171,838 shares of the medical instruments supplier’s stock worth $18,759,000 after purchasing an additional 128,033 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after purchasing an additional 115,141 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Analysts Set New Price Targets

LMAT has been the subject of several research reports. Citizens Jmp boosted their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research report on Wednesday, May 6th. Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Weiss Ratings lowered LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 6th. Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. Finally, Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $112.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.